

Faisal S Ali

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1135702/publications.pdf>

Version: 2024-02-01

54
papers

1,146
citations

840119

11
h-index

676716

22
g-index

54
all docs

54
docs citations

54
times ranked

1319
citing authors

#	ARTICLE	IF	CITATIONS
1	Factor Xa inhibitors versus low molecular weight heparin for the treatment of cancer associated venous thromboembolism; A meta-analysis of randomized controlled trials and non-randomized studies. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103526.	2.0	6
2	The conundrum in endoscopic management of duodenal polyps: a tertiary cancer center experience. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, 16, 569-576.	1.4	1
3	Diagnostic accuracy of narrow-band imaging endoscopy with targeted biopsies compared with standard endoscopy with random biopsies in patients with Barrett's esophagus: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2659-2671.	1.4	14
4	Cost-effectiveness analysis of optimal diagnostic strategy for patients with symptomatic cholelithiasis with intermediate probability for choledocholithiasis. <i>Gastrointestinal Endoscopy</i> , 2021, , .	0.5	7
5	Rate of colorectal neoplasia in patients with Hodgkin lymphoma. <i>Colorectal Disease</i> , 2020, 22, 154-160.	0.7	2
6	A Limited-Versus-Extensive Staging Strategy for Small Cell Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 87-93.	0.6	1
7	Immune-checkpoint inhibitors induced diarrhea and colitis. <i>Current Opinion in Gastroenterology</i> , 2020, 36, 25-32.	1.0	21
8	Patients with non-colorectal cancers may be at elevated risk of colorectal neoplasia. <i>Journal of Cancer</i> , 2020, 11, 3192-3198.	1.2	0
9	Reply to J. Delyon et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 3564-3565.	0.8	0
10	Safety and efficacy of metal stents for malignant colonic obstruction in patients treated with bevacizumab. <i>Gastrointestinal Endoscopy</i> , 2019, 90, 116-124.	0.5	24
11	Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 553-561.	2.0	57
12	Hepatobiliary Diseases in the Cancer Patient Leading to Critical Illness. , 2019, , 1-26.		0
13	Cerebral Radiation Necrosis: Incidence, Pathogenesis, Diagnostic Challenges, and Future Opportunities. <i>Current Oncology Reports</i> , 2019, 21, 66.	1.8	65
14	Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. <i>Journal of Clinical Oncology</i> , 2019, 37, 2738-2745.	0.8	138
15	Miliary Nodules in a Young Patient With AIDS: Not Always Tuberculosis. <i>American Journal of the Medical Sciences</i> , 2019, 357, e19-e20.	0.4	0
16	Major Stressful Life Events and Risk of Developing Lung Cancer: A Case-Control Study. <i>Clinical Medicine Insights: Oncology</i> , 2019, 13, 117955491983579.	0.6	8
17	Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. , 2019, 7, 93.		131
18	Safety of endoscopy in cancer patients with thrombocytopenia and neutropenia. <i>Gastrointestinal Endoscopy</i> , 2019, 89, 937-949.e2.	0.5	16

#	ARTICLE	IF	CITATIONS
19	Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 789-796.	0.6	12
20	Immune Checkpoint Inhibitor Induced Diabetes Mellitus Treated with Insulin and Metformin: Evolution of Diabetes Management in the Era of Immunotherapy. Case Reports in Oncological Medicine, 2019, 2019, 1-3.	0.2	9
21	Immune-mediated colitis after resumption of immune checkpoint inhibitor therapy.. Journal of Clinical Oncology, 2019, 37, 2577-2577.	0.8	2
22	Gastrointestinal, pancreatic, and hepatic toxicity profile of CTLA-4 immune checkpoint inhibitors alone and in combination with PD-1/PD-L1 inhibitors: A meta-analysis of clinical trials.. Journal of Clinical Oncology, 2019, 37, e14117-e14117.	0.8	4
23	Patients with breast cancer may be at higher risk of colorectal neoplasia. Annals of Gastroenterology, 2019, 32, 400-406.	0.4	5
24	Impact of pretreatment serum creatinine on outcomes in pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, e15749-e15749.	0.8	0
25	Inpatient outcome of solid tumor associated tumor lysis syndrome.. Journal of Clinical Oncology, 2019, 37, e18185-e18185.	0.8	0
26	The safety and tolerability of PD-1/PDL-1 inhibitors in hematologic malignancies: A meta-analysis.. Journal of Clinical Oncology, 2019, 37, e14131-e14131.	0.8	0
27	Outcomes after early initiation of nonsteroidal immunosuppressive therapy in patients with immune checkpoint inhibitor-induced colitis.. Journal of Clinical Oncology, 2019, 37, 2571-2571.	0.8	4
28	Risk of colon adenoma in patients with breast cancer.. Journal of Clinical Oncology, 2019, 37, 1541-1541.	0.8	0
29	Risk of colonic adenoma in patients with nonâ€“colorectal cancers.. Journal of Clinical Oncology, 2019, 37, e13070-e13070.	0.8	0
30	587â€“The Safety and Efficacy of Thalidomide for the Treatment of Gastrointestinal Bleeding Refractory to Endoscopic Intervention: A Meta-Analysis. American Journal of Gastroenterology, 2019, 114, S339-S340.	0.2	0
31	280â€“Patients With Non-Colorectal Cancers May Be at Elevated Risk of Colorectal Neoplasia. American Journal of Gastroenterology, 2019, 114, S163-S164.	0.2	0
32	279â€“Rate of Colorectal Neoplasia in Patients With Hodgkin Lymphoma. American Journal of Gastroenterology, 2019, 114, S162-S163.	0.2	0
33	Abstract 4189: Limited-versus-extensive staging system for small cell prostate cancer. , 2019, , .		0
34	Cognitive disability in adult patients with brain tumors. Cancer Treatment Reviews, 2018, 65, 33-40.	3.4	46
35	P105 SHORT TERM ENDOSCOPIC FOLLOW UP ON IMMUNO-CHECKPOINT INHIBITOR INDUCED COLITIS POST TREATMENT. Inflammatory Bowel Diseases, 2018, 24, S37-S37.	0.9	2
36	Clinical update on the management of pseudopapillary tumor of pancreas. World Journal of Gastrointestinal Endoscopy, 2018, 10, 145-155.	0.4	45

#	ARTICLE	IF	CITATIONS
37	Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. , 2018, 6, 142.		146
38	Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. , 2018, 6, 95.		146
39	P105 SHORT TERM ENDOSCOPIC FOLLOW UP ON IMMUNO-CHECKPOINT INHIBITOR INDUCED COLITIS POST TREATMENT. Gastroenterology, 2018, 154, S53-S54.	0.6	2
40	Ventral hernia recurrence in women of childbearing age: a systematic review and meta-analysis. Hernia: the Journal of Hernias and Abdominal Wall Surgery, 2018, 22, 1067-1075.	0.9	13
41	Su1346 - The Characteristics, Pathologic Predictors of Recurrence, and Utility of Surgical Resection of Solid Pseudopapillary Neoplasms: A 20 Year Experience at a Tertiary Cancer Center. Gastroenterology, 2018, 154, S-528.	0.6	0
42	Mo1322 THE DIAGNOSTIC VALUE OF EUS-FNA AND OUTCOMES IN PATIENTS WITH RARE PANCREATIC MALIGNANCIES. A 10-YEAR TERTIARY CARE CENTER EXPERIENCE. Gastrointestinal Endoscopy, 2018, 87, AB444-AB445.	0.5	0
43	Mo1325 DIAGNOSTIC VALUE OF EUS-FNA FOR METASTATIC LESIONS TO THE PANCREAS. A 10-YEAR TERTIARY CARE CENTER EXPERIENCE. Gastrointestinal Endoscopy, 2018, 87, AB445-AB446.	0.5	0
44	Mo1356 CHARACTERIZATION AND PREDICTORS OF DISEASE PROGRESSION IN PANCREATIC NEUROENDOCRINE TUMORS DIAGNOSED BY EUS-FNA. A 10-YEAR TERTIARY CARE CENTER EXPERIENCE. Gastrointestinal Endoscopy, 2018, 87, AB461.	0.5	0
45	Tu1434 THE SINGLE SESSION: FEASIBILITY AND OUTCOMES OF COMBINED EUS-FNA AND ERCP PROCEDURES. A 5-YEAR TERTIARY CARE CENTER EXPERIENCE. Gastrointestinal Endoscopy, 2018, 87, AB596-AB597.	0.5	0
46	Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. , 2018, 6, 37.		174
47	Tu1724 - Outcomes of Immunotherapy-Induced Diarrhea and Colitis: A Cancer Center Experience. Gastroenterology, 2018, 154, S-1001.	0.6	0
48	Outcomes of Vedolizumab Treatment in Patients With Immune Checkpoint Inhibitor-Induced Diarrhea and Colitis: A Multi-Center Study. American Journal of Gastroenterology, 2018, 113, S58.	0.2	1
49	The Impact of Immune Checkpoint Inhibitor-Related Adverse Events and Their Immunosuppressive Treatment on Patients's Outcomes. Journal of Immunotherapy and Precision Oncology, 2018, 1, 7-18.	0.6	40
50	Taming the Beast: The Safety and Efficacy of Fecal Microbiota Transplantation in Severe and Complicated Clostridium difficile Infection. American Journal of Gastroenterology, 2018, 113, S113-S115.	0.2	0
51	The Importance of Endoscopic and Histological Evaluation in the Management of Immune Checkpoint Inhibitor-Induced Colitis. American Journal of Gastroenterology, 2018, 113, S112-S113.	0.2	1
52	Fecal Microbiota Transplantation for Clostridium difficile Infection in Immunocompromised Patients - Safe or Risky?. American Journal of Gastroenterology, 2018, 113, S115-S117.	0.2	0
53	Fearing the Unknown - The Fate of Inflammatory Bowel Disease After Fecal Microbiota Transplantation for Clostridium difficile Infection. American Journal of Gastroenterology, 2018, 113, S409-S411.	0.2	0
54	Major stressful life events and risk of developing lung cancer.. Journal of Clinical Oncology, 2017, 35, 1575-1575.	0.8	3